Miruvor
Sign up
The short answer

What studies of nerve blocks (occipital, head and neck) found

4papers on nerve blocks (occipital, head and neck)
1 (few people)person in 1 study testing nerve blocks (occipital, head and neck) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 5 findings, all C.

5 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Nerve blocks (occipital, head and neck) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 4 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Nerve blocks (occipital, head and neck) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Breathlessness1 study · 1 (few people) person received nerve blocks (occipital, head and neck) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side (few people)

Breathlessness improved.

The evidence is very uncertain about the effect of nerve blocks (occipital, head and neck) on breathlessness in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Sphenopalatine Ganglion Block for Postacute Sequelae SARS-CoV-2 Infection Headaches: A Case Report and Review of the Literature. (2023)

    People in the study
    1 in the study
    Dose
    2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side
    Outcome
    sinus congestion
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 1 (few people) person received nerve blocks (occipital, head and neck) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side (few people)

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of nerve blocks (occipital, head and neck) on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Sphenopalatine Ganglion Block for Postacute Sequelae SARS-CoV-2 Infection Headaches: A Case Report and Review of the Literature. (2023)

    People in the study
    1 in the study
    Dose
    2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side
    Outcome
    concentration
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person received nerve blocks (occipital, head and neck) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side (few people)

Pain improved.

The evidence is very uncertain about the effect of nerve blocks (occipital, head and neck) on pain in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Sphenopalatine Ganglion Block for Postacute Sequelae SARS-CoV-2 Infection Headaches: A Case Report and Review of the Literature. (2023)

    People in the study
    1 in the study
    Dose
    2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side
    Outcome
    eye pain on the right
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Smell and taste loss1 study · 1 (few people) person received nerve blocks (occipital, head and neck) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side (few people)

Smell and taste loss improved.

The evidence is very uncertain about the effect of nerve blocks (occipital, head and neck) on smell and taste loss in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Sphenopalatine Ganglion Block for Postacute Sequelae SARS-CoV-2 Infection Headaches: A Case Report and Review of the Literature. (2023)

    People in the study
    1 in the study
    Dose
    2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side
    Outcome
    anosmia
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms1 study · 1 (few people) person received nerve blocks (occipital, head and neck) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of nerve blocks (occipital, head and neck) on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Sphenopalatine Ganglion Block for Postacute Sequelae SARS-CoV-2 Infection Headaches: A Case Report and Review of the Literature. (2023)

    People in the study
    1 in the study
    Dose
    2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine, right side; left side
    Outcome
    most symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    10 mg at the start

  2. 2Top dose

    Most often 10 mg (1 of 1 studies)

Doses across 1 study

10 to 10 mg.

Each study’s dose, as printed

All papers

  1. Stellate Ganglion Block Relieves Long COVID-19 Symptoms in 86% of Patients: A Retrospective Cohort Study.2023 · no comparison group · 60 in the study · 41 with outcome data
    Summary

    This retrospective cohort study in Colorado clinics included self-referred patients with long COVID-19 symptoms. Of 60 treated patients, 41 (18 male and 23 female) responded to post-procedure follow-up and were analysed. Patients received ultrasound-guided stellate ganglion block (SGB) with 2 ml 2% chloroprocaine, 2 ml 1% lidocaine, and 1 ml 0.2% ropivacaine; blocks were unilateral or bilateral. There was no comparison group. Symptoms were recorded as present before SGB and improved or unchanged after SGB; follow-up timing varied with patient response times. The study reports that 86% reported a reduction in at least some symptoms, and 25 patients (61% of the total 41 patients) reported relief from all symptoms they initially presented with. Table 2 reports relief for fatigue in 77% and brain fog in 79%; the text reports 80% for brain fog. Six patients failed to experience symptom relief. Two patients experienced a return of symptoms as of September 2023. Three patients had a vagal response and four had transient hoarseness; the authors state the technique did not result in any significant adverse events.

  2. Sphenopalatine Ganglion Block for Postacute Sequelae SARS-CoV-2 Infection Headaches: A Case Report and Review of the Literature.2023 · case report · 1 in the study
    Summary

    This case report describes 1 patient in her 50s with postacute sequelae SARS-CoV-2 infection (PASC), or Long COVID, who was referred from the PASC clinic to the interventional pain clinic for persistent symptoms including headaches. There was no comparison group and no randomisation. The experimental treatment was a sphenopalatine ganglion block (SPGB) via an infrazygomatic approach, using a 2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine; the right side was treated first and then the left side. Background treatments included right and left stellate ganglion blocks, which temporarily relieved most symptoms for 2 weeks and completely resolved the anosmia and ageusia. After the right-sided SPGB, the patient reported more than an 80% improvement in headaches, blurry vision, and eye pain on the right, and significant improvement in sinus congestion, concentration, and short-term memory; the left-sided SPGB resulted in similar relief. The abstract reports an 80% improvement in symptoms after bilateral SPGB. To date, the patient still has significant relief with no refractory symptoms. Conservative therapies had minimal effects; LDN and mesenchymal stem cells gave short-term symptom relief; intravenous nicotinamide adenine dinucleotide therapy gave no alleviation in the last 2 months. No harms were described, and withdrawal from treatment was not reported. The patient was very pleased with the results of the injections into her nose. The authors state the single case is empirical until further case reports or series show similar benefits.

  3. Sympathetic and Parasympathetic Ganglion Blocks for Treatment of Long COVID-19 Symptoms: A Scoping Review.2026 · review
    Summary

    This scoping review examined sympathetic and parasympathetic ganglion blocks for long COVID-19, a condition associated with persistent functional impairment and reduced quality of life. It included 22 articles covering 505 patients treated in outpatient clinics where they received sympathetic blocks or parasympathetic blocks. The most commonly utilized intervention was the stellate ganglion block. The most frequently studied symptoms were olfactory dysfunction, fatigue, headache, and cognitive disturbances. The review's objective was to assess effectiveness by identifying commonly reported symptoms, symptom response to different block regimens, and adverse effects. No comparison group and no randomised design were reported. The abstract did not report a quantitative comparison, worsening, stopping treatment, side-effect counts, or follow-up duration. The authors concluded that stellate ganglion blocks may offer therapeutic benefit for dysautonomia and cognitive dysfunction associated with long COVID-19, and that sphenopalatine ganglion blocks have shown promise for refractory headache symptoms in this population. They stated that variations in treatment regimens precluded a quantitative analysis and that reporting bias from case reports and small observational studies should be considered.

  4. A Review of Stellate Ganglion Block as an Adjunctive Treatment Modality.2023 · review
    Summary

    This narrative review summarizes stellate ganglion block (SGB) as an adjunctive modality for a select group of esoteric conditions, including anosmia, PTSD, long-COVID, chronic fatigue syndrome, menopausal hot flashes, and ventricular tachyarrhythmias. The review reports no enrolled, started, or analysed number for its own study. Among named studies, Liu and Duricka described three patients with long-COVID; after SGB and then a contralateral injection 24-72 hours later, all three experienced sustained symptomatic relief at a 60-day follow-up. Vinyes et al. described a long-COVID patient treated with 0.5% procaine for both SGB and sphenopalatine ganglion block three times over three months, with complete resolution of fatigue. A double-blind, placebo-controlled study in CFS compared lidocaine injections into the trapezius and gluteal muscles with saline; there was a significant 38% reduction in fatigue scores in the treatment group. Harms reported for SGB include hoarseness and lightheadedness as the most common systemic complications, severe HTN following SGB in case reports, short-term and persistent coughs, local blood aspiration, intra-procedural bleeding, and hematoma formation, and five case reports of delayed hematoma formation requiring tracheostomy and prolonged hospitalization. Bhatia et al. demonstrated vertebral artery vulnerability in approximately 12% of cases involving ultrasound-guided SGB. Adverse events typical for other SGB utilizations include cough, hoarseness, pain/redness at the injection site, and vasovagal syncope following intravenous catheter insertion. The authors state that current literature is limited and that large multicenter randomized controlled trials are needed; no withdrawals were reported in the recorded data.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime